Cardio Diagnostics

Cardio Diagnostics

Health Care Providers and Services
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases. The company offers three AI-powered solutions for the risk assessment, detection, management, and monitoring of coronary heart diseases. These solutions are Epi+Gen CHD, a symptomatic CHD risk assessment clinical blood test targeting CHD events; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform coupled to the Epi+Gen CHD and PrecisionCHD tests that provide personalized insights by linking the epigenetic and genetic biomarkers evaluated by these tests to the drivers of coronary heart disease.

2021

(5 years)

Founded

2022

(4 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

—

P/S

3,2

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

4

EPS

—

Market Cap

Market Cap

47,3K

EV

-4,6M

EV/Revenue

-310,6

EV/EBITDA

0,8

EV/EBIT

0,7

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-8042,1%

Total Yield

-8042,1%

Payout

0%

Retained Earnings

-29,2M

Profitability

Gross Margin

100%

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

4325,2%

Capex/Revenue

1263,5%

Capex/D&A

47%

Capex/OCF

-3,3%

SBC/OCF

—

% PPE

12,4%

% Goodwill

0%

ROE

—

ROIC

—

Growth

CAGR Op. Income 5Y

60,5%

CAGR Net Income 5Y

60,8%

Leverage

N.D./EBITDA

0,8

Debt/Equity

0%

Current Ratio

9,8

Quick Ratio

8,5

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium